Replies to post #380538 on $Rig's Platinum Penny Alerts

[RIGATONI]

And this tweet I just noticed from the CEO...

$CVM Thank you for the go-ahead from FDA for the confirmatory trial. We already know how the selected patients did in the completed study. 73% survival with Multikine vs 45% without Multikine. We can help a lot of patients. I believe! So I bought more stock.

— Geert Kersten (@GeertKersten1) May 9, 2024